To ascertain whether higher levels of Bim sensitize hepatoma cells to chemotherapeutic drugs or tumor-killing cytokines, Bim-S was overexpressed via adenoviral transduction in HepG2 and Sk-Hep1 cell lines displaying low Bim expression, followed by challenge with the anticancer drugs cisplatin, doxorubicin or recombinant (r)-TRAIL (Figure 4b). Here, BCL2L11 is linked to neoplasm.